melanotan-2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
=== Dextran conjugate nanoparticles === Dextran conjugates are also utilized in nanoparticle drug delivery system formulations. Nanoparticles composted of dextran and stearic acid with a polyethylene glycol (PEG) coating can be loaded with antiviral drugs and be effectively internalized by cells. This nanosystem has the advantages of providing protection against immune responses and providing stability to the encapsulated drug. This technology has applications in the treatment of HIV and AIDS. Dextran can be grafted with folic acid to develop doxorubicin-loaded nanoparticles. Dextran-folic acid nanoparticles effectively target tumors, reduce off-site toxicity, and prolong blood circulation. Dextran-spermine nanoparticles loaded with doxorubicin can achieve targeted and sustained drug release in tumors.
=== Probing pocket depth (PPD) === Pocket depth is the distance from the gingival margin to the base of the pocket. The position of the gingival margin can change due to swelling or recession, and vary with inflammation if force of probing, therefore, probing depth measurement alone is not recommended for assessment of changes in periodontal support over time.
Drew insisted that there was no racial difference in human blood and that the policy would lead to needless deaths as soldiers and sailors were required to wait for "same race" blood. By the end of the war the American Red Cross had provided enough blood for over six million plasma packages. Most of the surplus plasma was returned to the United States for civilian use. Serum albumin replaced dried plasma for combat use during the Korean War.
=== Ceasefire attempts === Syrian minister of defense Murhaf Abu Qasra announced a ceasefire effective from 15 July 2025 after an agreement with the Druze leaders in Suwayda. The Syrian Ministry of Interior warned against any damage to private or public property in Suwayda. According to the ceasefire agreement, it was not a complete withdrawal of the administration, and it would be able to continue to maintain police forces in the district, which would operate together with local Druze, but it was required, as stated, to withdraw the military forces it had sent there in the battles in recent days. A mechanism was also agreed upon to regulate the issue of possession of heavy weapons in the area. The agreement also stipulates the establishment of an investigative committee that will examine atrocities committed by militants and regime members against the Druze, according to reports. Following the second ceasefire announced on 16 July 2025, Syrian president Ahmed al-Sharaa addressed the nation stating that the government's priority is to protect Druze citizens as Israel continues its assaults on Syria. He further said "we reject any attempt to drag you into hands of an external party. We are not among those who fear the war. We have spent our lives facing challenges and defending our people, but we have put the interests of the Syrians before chaos and destruction".
Sources: en.wikipedia.org
=== COVID-19 pandemic === In April 2020, Gavi's CEO Seth Berkley commented that the COVID-19 pandemic needed a global response whereby the best global facilities for separate parts of the processes should then be integrated into a global process. He said he hoped that the G20 countries should work together with a budget of tens of billions of dollars, and that individual countries should be prepared for finished vaccines to be allocated according to greatest need. In September 2020, Gavi was announced as one of the organisations leading the COVAX vaccine allocation plan, created to ensure that any new COVID-19 vaccine would be shared equally between the world's richest and poorest countries. The following month, Gavi announced the approval of up to $150 million to help 92 low- and middle-income countries prepare for the delivery of future COVID-19 vaccines, including technical assistance and cold chain equipment. In January 2021, Seth Berkley announced that Gavi hoped to deliver 145 to 150 million doses of COVID-19 vaccines in the first quarter of 2021 and 500 million doses in the second quarter, and then 1.5 billion in the second half of the year. In January 2022, The Washington Post reported that following 309 million coronavirus vaccine doses being delivered in December 2021, COVAX had delivered over 1 billion for the pandemic.
In 2001, the LRP-I was merged with the MCW to create the consolidated Meal, Cold Weather/Food Packet, Long Range Patrol (MCW/LRP) ration. As in years past, this was done in order to further standardize supply and save costs, as both were considered compact, high-energy meals that were designed for use by active soldiers in the field. The meal weighs 1 pound (454 g) and comes in 12 different entrees. The meals differ only in the accessory packs. One is geared for use by light infantry and commando units operating in temperate or hot climates and comes in brown or tan packaging. The other is geared more for use in cold weather or high elevations and comes in white packaging.
==== Cuba (1955-56) ==== In the winter of 1955–56, Mizell resumed his professional baseball career in Cuba, where he emerged as one of the Cuban League's most popular players. He set records for most strikeouts in a game (15) and in a season (206). With a 12–9 record and a 2.16 ERA, he finished second in most valuable player (MVP) voting. In February, his wife gave birth to their first son. Mizell found out during one of the games and, according to one story, was so excited that he absentmindedly went to hit holding his glove instead of a baseball bat.
sticky end A term used to describe the end of a double-stranded DNA molecule where one strand is longer than the other by one or more nucleobases, creating a single-stranded "overhang" of unpaired bases, in contrast to a so-called blunt end, where no such overhang exists because the terminal nucleobases on each strand are base-paired with each other. Blunt ends and sticky ends are relevant when ligating linear DNA molecules, e.g. in restriction cloning, because many restriction enzymes cleave the phosphate backbone in a way that leaves behind terminal overhangs in the digested fragments. These sticky-ended molecules ligate much more readily with other sticky-ended molecules having complementary overhangs, allowing scientists to ensure that specific DNA fragments are ligated together in specific places.
=== Exposure route considerations in CNT toxicology === Pulmonary exposure: Inhalation of airborne CNTs during manufacturing or handling poses the highest risk. CNTs can induce dose-dependent pulmonary toxicity, including granuloma formation, fibrosis, and inflammation. MWCNTs, due to their fiber-like structure, are particularly prone to eliciting asbestos-like responses. SWCNTs may translocate systemically but generally exhibit less chronic pulmonary toxicity. Dermal and consumer exposure: Intact skin provides a barrier to CNT penetration, though localized cutaneous inflammation has been reported while evidence suggests limited systemic health impact. Oral and systemic exposure: Oral ingestion of CNTs typically results in low bioavailability and rapid excretion, with significant effects observed only at high doses. Systemic exposure via intravenous or intraperitoneal routes is primarily relevant in experimental or therapeutic contexts.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.